Fortrea vs Medpace
FTRE and MEDP side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FTRE and MEDP compare
Medpace is the larger company, worth 9.0 times as much as Fortrea ($18.2B against $2.0B).
Medpace grew revenue faster over the last twelve months (24.7% versus −3.4% for Fortrea).
Medpace keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with −2.6% at Fortrea.
Medpace scores higher on the StockData Score (15 against 4 for Fortrea), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FTRE | MEDP |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $18.2B |
| Share price | $21.29 | $652.01 |
| Change, 1 year | 104% | 11.5% |
| Change, 5 years | – | 189% |
| Beta (5Y) | 1.49 | 1.39 |
| Employees | 14K | 6,200 |
| StockData Score | ||
| Total score | 4 | 15 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 38.2× |
| P/S | 0.8× (better) | 6.5× |
| P/B | 3.8× (better) | 41.9× |
| EV/EBITDA | 31.3× | 30.3× (better) |
| P/FCF | 12.0× (better) | 25.8× |
| PEG | – | 1.36 |
| FCF yield | 8.3% (better) | 3.9% |
| Fair value | $17.16 | $430.99 |
| Margin of safety | −24.1% (better) | −51.3% |
| Growth | ||
| Revenue growth (TTM) | −3.4% | 24.7% (better) |
| Revenue growth, 5Y average | – | 22.3% |
| Net income growth (TTM) | – | 17.5% |
| EPS growth (TTM) | – | 26.8% |
| EPS growth, 5Y average | – | 31.8% |
| Profitability | ||
| Gross margin | 20.0% | – |
| Operating margin | 0.48% | 21.0% (better) |
| Net margin | −2.6% | 17.7% (better) |
| FCF margin | 6.3% | 25.4% (better) |
| Return on equity | −12.3% | 162% (better) |
| Return on invested capital | 0.69% | 1674% (better) |
| Financial health | ||
| Debt / equity | 1.98 (better) | 0.00 |
| Net debt / EBITDA | 9.12 | – |
| Current ratio | 0.97 (better) | 0.73 |
| Altman Z-score | 0.80 | 8.44 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 1.6% |
| Shareholder yield | 0.00% | 1.6% (better) |
| Ownership | ||
| Held by institutions | 105% | 88.5% |
| Held by insiders | 4.0% | 20.1% |
| Insider net buying, 12 months | −$4.7M (better) | −$409M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 13.8% | 7.2% |
Go deeper
- FTRE stock overview
- FTRE income statement
- FTRE valuation and score
- MEDP stock overview
- MEDP income statement
- MEDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.